Candel therapeutics announces can-2409 achieved primary endpoint in phase 3 prostate cancer trial, showing significantly improved disease-free survival

Needham, mass., dec. 11, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced results from a multicenter phase 3 clinical trial evaluating can-2409 viral immunotherapy in localized prostate cancer patients.
CADL Ratings Summary
CADL Quant Ranking